FR3121040B1 - BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS - Google Patents

BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS Download PDF

Info

Publication number
FR3121040B1
FR3121040B1 FR2012114A FR2012114A FR3121040B1 FR 3121040 B1 FR3121040 B1 FR 3121040B1 FR 2012114 A FR2012114 A FR 2012114A FR 2012114 A FR2012114 A FR 2012114A FR 3121040 B1 FR3121040 B1 FR 3121040B1
Authority
FR
France
Prior art keywords
treatment
biological
keratitis
amoebic
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2012114A
Other languages
French (fr)
Other versions
FR3121040A1 (en
Inventor
Mondher Boughalmi
Ep Boughalmi Hanene Saadi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarl Bioamar
Original Assignee
Sarl Bioamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarl Bioamar filed Critical Sarl Bioamar
Priority to FR2012114A priority Critical patent/FR3121040B1/en
Publication of FR3121040A1 publication Critical patent/FR3121040A1/en
Application granted granted Critical
Publication of FR3121040B1 publication Critical patent/FR3121040B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un composé biologique de traitement destiné pour les patients atteints de la kératite amibienne qui se base sur une solution virale contenant un virus non pathogène humain nommé Keratovirus appartenant au groupe Tunisvirus de la famille Marseilleviridae. Il s’agit du premier produit biologique destiné pour le traitement de la kératite amibienne basé sur une composition virale. Il s’agit donc du premier amibicide biologique efficace contre les deux formes d’amibes à savoir la forme “trophozoîte” active et la forme “kyste” dormant. Cette invention concerne l’utilisation biotechnologique des virus pour traiter et lutter contre les infections amibiennes et pour toute autre utilisation environnementale, technologique et industrielle. Listes des FiguresThe present invention relates to a biological treatment compound intended for patients suffering from amoebic keratitis which is based on a viral solution containing a non-pathogenic human virus named Keratovirus belonging to the Tunisvirus group of the Marseilleviridae family. This is the first biological product intended for the treatment of amoebic keratitis based on a viral composition. It is therefore the first biological amoebicide effective against both forms of amoebae, namely the active “trophozoite” form and the dormant “cyst” form. This invention relates to the biotechnological use of viruses to treat and combat amoebic infections and for any other environmental, technological and industrial use. Lists of Figures

FR2012114A 2020-11-25 2020-11-25 BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS Active FR3121040B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2012114A FR3121040B1 (en) 2020-11-25 2020-11-25 BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2012114 2020-11-25
FR2012114A FR3121040B1 (en) 2020-11-25 2020-11-25 BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS

Publications (2)

Publication Number Publication Date
FR3121040A1 FR3121040A1 (en) 2022-09-30
FR3121040B1 true FR3121040B1 (en) 2023-11-10

Family

ID=81648392

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2012114A Active FR3121040B1 (en) 2020-11-25 2020-11-25 BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS

Country Status (1)

Country Link
FR (1) FR3121040B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806741B2 (en) * 2018-09-24 2020-10-20 Profounda, Inc. Treatments for free-living amoebic infections

Also Published As

Publication number Publication date
FR3121040A1 (en) 2022-09-30

Similar Documents

Publication Publication Date Title
Schröfelbauer et al. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases
EA200701297A1 (en) COMPOUNDS OF PYRIDAZINON
TNSN06051A1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS
MA33209B1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
MA27347A1 (en) HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THEM, PHARMACEUTICAL USES THEREOF AND MATERIALS FOR THEIR SYNTHESIS
Xiang et al. An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells
Assetta et al. JC polyomavirus infection of primary human renal epithelial cells is controlled by a type I IFN-induced response
TNSN07233A1 (en) MACROLIDE
MA46230A (en) TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS
Mansharamani et al. Barrier-to-Autointegration Factor BAF Binds p55 Gagand Matrix and Is a Host Component of Human ImmunodeficiencyVirus Type 1Virions
ATE494373T2 (en) METHODS AND COMPOSITIONS FOR REDUCING AMOUNTS OF HCV VIRUS IN A TARGET CELL
EA200700338A1 (en) INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF THE VIRUS HEPATITIS C AND COMPOSITIONS AND METHODS OF TREATMENT USING THEM
BG100455A (en) Hiv protease inhibitors
ES2139195T3 (en) SULFONAMID DERIVATIVES AS ASPARTIL-PROTEASE INHIBITORS.
CA2335903A1 (en) Novel cyclosporin with improved activity profile
DE602004023932D1 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TNSN06370A1 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
Nchioua et al. SARS-CoV-2 variants of concern hijack IFITM2 for efficient replication in human lung cells
Cubas et al. The dysfunction of T follicular helper cells
ES2151600T3 (en) DERIVATIVES OF N- (3-AMINO-2-HYDROXIBUTE) SULFONAMIDE USED AS HIV PROTEASE INHIBITORS.
FR3121040B1 (en) BIOTECHNOLOGICAL PREPARATION FOR THE TREATMENT OF AMEBIC KERATITIS
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ATE498398T1 (en) CYCLOALKYL HETEROCYCLES FOR THE TREATMENT OF HEPATITIS C VIRUS
Li et al. The chaperone protein p32 stabilizes HIV-1 Tat and strengthens the p-TEFb/RNAPII/TAR complex promoting HIV transcription elongation
BRPI0414199A (en) hiv virus entry inhibitors

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20220930

PLFP Fee payment

Year of fee payment: 5